title: Health-related quality of life in psoriatic arthritis patients in Spain.
abstract: OBJECTIVE
  To describe the demographic and clinical characteristics, including health-related quality-of-life (HRQL), in patients with psoriatic arthritis (PsA).
  
  
  METHODS
  287 patients from 18 Spanish centres were assessed. PsA severity was measured using the following criteria: (1) Psoriasis Area and Severity Index (PASI score 0-72, from low to high severity); (2) number of swollen and tender joints; and (3) Health Assessment Questionnaire (HAQ score 0-3 from low to high impairment in daily activities). HRQL assessment was performed using the following criteria: (a) EuroQol-5D (EQ-5D scores 1-3, with a higher score representing a worse HRQL), Visual Analogue Scale (VAS score 0-100, with a higher score representing a better HQRL) and (b) Short Form-36 (SF-36 score 0-100, with a higher score representing a better HRQL).
  
  
  RESULTS
  24.7% of patients were treated with infliximab. In the two groups, 55.7% of the patients were male with a mean age of 52.40±12.53 years. The average number of swollen joints was higher in patients not receiving biological therapy than in those receiving treatment (2.98 vs. 1.54). The mean PASI score was 3.73±5.83, and there was no difference between groups. HAQ scores were higher in patients receiving infliximab than in those not receiving treatment (0.93 vs. 0.70). The mean EQ-5D scores in the two groups indicated a poorer status based on pain and inability to perform usual/daily activities. HRQL measured by VAS score mean was 60.41 ± 20.08, and there was no difference between the groups. The domains in the SF-36 suggesting poorer functioning in the two groups were the physical role (50.76 ± 43.43), physical pain (49.35 ± 25.69) and the overall physical component (37.88 ± 10.87).
  
  
  CONCLUSIONS
  PsA is associated with an impaired HRQL characterised by physical pain and poorer functioning in daily activities.
authors.affiliation: Servicio de Reumatología, Hospital Parc Taulí, Sabadell, Barcelona, Spain. Electronic address: jgratacosmas@gmail.com.
authors.forename: Jordi
authors.initials: J
authors.lastname: Gratacós
authors.affiliation: Servicio de Dermatología, Hospital de la Princesa, Madrid, Spain.
authors.forename: Esteban
authors.initials: E
authors.lastname: Daudén
authors.affiliation: Servicio de Reumatología, Complexo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Gómez-Reino
authors.affiliation: Servicio de Dermatología, Hospital Reina Sofía, Córdoba, Spain.
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Moreno
authors.affiliation: Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Casado
authors.affiliation: Servicio de Reumatología, Hospital Marqués de Valdecilla, Santander, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Rodríguez-Valverde
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D011788:Quality of Life; D012720:Severity of Illness Index; D013030:Spain; D011795:Surveys and Questionnaires
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab
keywords: Artritis psoriásica; Biological therapies; Calidad de vida; EQ-5D; Infliximab; Psoriatic arthritis; Quality-of-life; SF-36; Terapias biológicas